Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration
Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration
复制标题
DOI：
10.1007/s00535-005-1577-0
复制
发表时间：
2005-05-01
影响因子：
6.3
通讯作者：
Sasaki, K
中科院分区：
文献类型：
--
作者：
Kitoh, H;Ryozawa, S;Sasaki, K
背景：胰腺癌的比较基因组杂交（CGH）分析仅用于手术和尸检标本，因为非手术组织取样困难。为了克服这一困难，我们将CGH技术应用于通过内窥镜超声引导细针穿刺（EUS-FNA）获得的细胞。方法.在本研究中，我们对17例胰腺癌患者在手术前进行了EUS-FNA。通过显微切割选择肿瘤细胞。从细胞中提取DNA并通过简并寡核苷酸引物聚合酶链反应（DOP-PCR）扩增。然后进行CGH。结果在15例管状腺癌患者中，最常见的增益位点（包括扩增）是5 p，8 q和20 q（60%的患者）; 1 q，7 p和12 p（27%）。最常见的丢失是17 p（73%）; 9 p，18 q和19 p（47%）;和8 p（33%）。这些发现与我们以前报告的数据相似。两例腺泡细胞癌患者的2 q和5 p增加，1 p、9 p、9 q、11 p、11 q、14 q、17 p、17 q和18 q丢失。结论.这项研究的结果表明，综合遗传分析是可能的EUS-FNA活检标本，显微切割和DOP-PCR相结合。这种分析策略将使我们能够在治疗前评估胰腺癌的生物学特征。
Background Comparative genomic hybridization (CGH) analysis of pancreatic cancer has been done exclusively for surgical and autopsy specimens, because of the difficulty of tissue sampling without surgery. To overcome this difficulty, we applied CGH technology to cells obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Methods. In the present study, we performed EUS-FNA for 17 patients with pancreatic cancer before surgery. Tumor cells were selected by microdissection. DNA was extracted from the cells and amplified by degenerate oligonucleotide-primed polymerase chain reaction (DOP-PCR). Then CGH was carried out. Results. In the 15 patients with tubular adenocarcinoma, the most common loci of gains (including amplification) were 5p, 8q, and 20q (60% of the patients); and 1q, 7p, and 12p (27%). The most frequent losses were 17p (73%); 9p, 18q, and 19p (47%); and 8p (33%). These findings were similar to our previously reported data. Both of the patients with acinar cell carcinoma showed gains of 2q and 5p, and losses of 1p, 9p, 9q, 11p, 11q, 14q, 17p, 17q, and 18q. Conclusions. The results of this study suggest that comprehensive genetic analysis is possible for EUS-FNA biopsy specimens, with a combination of microdissection and DOP-PCR. This analytical strategy will enable us to evaluate the biological characteristics of pancreatic cancer before treatment.